You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Clinical management, expectations, and satisfaction of patients with moderate to severe allergic rhinoconjunctivitis treated with SQ-standardized grass-allergen tablet under routine clinical practice conditions in Spain
|
|---|---|
| Published in |
Clinical and Molecular Allergy, January 2017
|
| DOI | 10.1186/s12948-016-0057-9 |
| Pubmed ID | |
| Authors |
Tomás Chivato, Pedro Álvarez-Calderón, Carmen Panizo, Ricardo Abengozar, César Alías, Ali Al-Baech, José Arias-Irigoyen, M. José Caballero, Lluis Conill, Silvia de Miguel, Rafael Laguna, Joan Martínez-Benazet, Francisco Matoses, Jose Camilo Martínez-Alonso, Lourdes Mendizábal, Celsa Pérez-Carral, Carlos Puerto, Joan Serra-Batllés, Adolfo Vélez, Jonathan Vicente, Fernando de la Torre |
| Abstract |
Sublingual immunotherapy has been proven as a well-tolerated and effective treatment for allergic rhinitis. Within this type of treatment, GRAZAX(®) is the most documented product in terms of safety and efficacy. The objective of this study was to identify the patients' expectations and level of treatment satisfaction, as well as the clinical management of patients with moderate/severe allergic rhinoconjunctivitis treated with GRAZAX(®). This was a non-interventional, observational, multi-centre, open-label study involving a total of 131 adult patients aged 18-66 years with confirmed diagnosis of grass-allergy and initiated treatment with GRAZAX(®) between June 2010 and April 2011. In the pollen season after starting treatment, 56.6% of patients stated that their symptoms were much less/less intense, 86% needed less symptomatic medication for control of their symptoms, and 74.4% manifested to have improved (quite/a lot) as regards their allergic disease since treatment was initiated as compared with previous grass pollen season. The patient satisfaction with GRAZAX(®) was measured using a visual analogue scale (VAS) between 0 (minimum satisfaction) and 100 (maximum satisfaction) comprising five different items: effectiveness, tolerability, cost, convenience and overall satisfaction. The results obtained for each item were [mean (SD)]: 74.7 (18.1), 70.3 (36.1), 39.3 (25.8), 86.2 (12.6), 78.4 (15.8) respectively. The patient's level of satisfaction is highly influenced, especially in terms of assessment of effectiveness, tolerability and convenience, by the information provided by the specialist. In summary, it can be concluded that improved communication leads to increased patient knowledge, greater patient compliance, and increased patient satisfaction. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Science communicators (journalists, bloggers, editors) | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 28 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Unspecified | 10 | 36% |
| Student > Bachelor | 4 | 14% |
| Student > Ph. D. Student | 3 | 11% |
| Student > Postgraduate | 2 | 7% |
| Other | 1 | 4% |
| Other | 2 | 7% |
| Unknown | 6 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Unspecified | 10 | 36% |
| Medicine and Dentistry | 5 | 18% |
| Agricultural and Biological Sciences | 2 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 7% |
| Immunology and Microbiology | 2 | 7% |
| Other | 1 | 4% |
| Unknown | 6 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 December 2020.
All research outputs
#3,811,660
of 22,947,506 outputs
Outputs from Clinical and Molecular Allergy
#60
of 214 outputs
Outputs of similar age
#76,395
of 420,539 outputs
Outputs of similar age from Clinical and Molecular Allergy
#2
of 5 outputs
Altmetric has tracked 22,947,506 research outputs across all sources so far. Compared to these this one has done well and is in the 82nd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 214 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.1. This one has gotten more attention than average, scoring higher than 70% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 420,539 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than 3 of them.